BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
DOI:
https://doi.org/10.2340/actadv.v104.18389Keywords:
Herpes zoster, COVID-19, Pfizer–BioNTech COVID-19 (BNT162b2) vaccineAbstract
Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus. Recent observations have suggested that HZ is associated with vaccination against COVID-19. To investigate the association between the vaccine and HZ severity, a single-centre, cross-sectional study of all patients diagnosed with HZ and 2 control diagnoses (cellulitis and bone fractures), between 2017 and 2021, was performed. Hospital visits and hospitalization rates were compared. All medical records of patients diagnosed with HZ in the first year after the COVID-19 vaccination campaign began were reviewed, in order to generate a retrospective cohort comparing vaccinated and unvaccinated patients with HZ. All participants had received the Pfizer–BioNTech COVID-19 (BNT162b2) vaccine. During the study period, 2,413 patients were diagnosed with HZ, and when normalized to control diagnoses the number of cases remained stable. The retrospective cohort included 365 patients. A multivariate analysis controlling for sex, age, autoimmune diseases, malignancies, and immunosuppressive therapy showed higher admission rates in vaccinated compared with unvaccinated individuals (odds ratio (OR) 2.75, 95% CI 1.27–5.96, p = 0.01). However, matching techniques and stratification by age, used to better control for confounders, invalidated these findings. No differences were observed in other variables indicative of disease severity (hospital stay length and complications). In conclusion, COVID-19 vaccination was not found to be associated with an increased risk of HZ-related admission and complications.
Downloads
References
Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007; 57: S130-S135.
https://doi.org/10.1016/j.jaad.2007.08.046 DOI: https://doi.org/10.1016/j.jaad.2007.08.046
Brambilla L, Maronese CA, Tourlaki A, Veraldi S. Herpes zoster following COVID-19: a report of three cases. Eur J Dermatol 2020; 30: 754.
https://doi.org/10.1684/ejd.2020.3924 DOI: https://doi.org/10.1684/ejd.2020.3924
Maia CMF, Marques NP, de Lucena EHG, de Rezende LF, Martelli DRB, Martelli-Júnior H. Increased number of herpes zoster cases in Brazil related to the COVID-19 pandemic. Int J Infect Dis 2021; 104: 732-733.
https://doi.org/10.1016/j.ijid.2021.02.033 DOI: https://doi.org/10.1016/j.ijid.2021.02.033
Pona A, Jiwani RA, Afriyie F, Labbe J, Cook PP, Mao Y. Herpes zoster as a potential complication of coronavirus disease 2019. Dermatol Ther 2020; 33: e13930.
https://doi.org/10.1111/dth.13930 DOI: https://doi.org/10.1111/dth.13930
Tartari F, Spadotto A, Zengarini C, Zanoni R, Guglielmo A, Adorno A, et al. Herpes zoster in COVID-19-positive patients. Int J Dermatol 2020; 59: 1028-1029.
https://doi.org/10.1111/ijd.15001 DOI: https://doi.org/10.1111/ijd.15001
Walter R, Hartmann K, Fleisch F, Reinhart WH, Kuhn M. Reactivation of herpesvirus infections after vaccinations? Lancet 1999; 353: 810.
https://doi.org/10.1016/S0140-6736(99)00623-6 DOI: https://doi.org/10.1016/S0140-6736(99)00623-6
Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med 2021; 385: e85.
https://doi.org/10.1056/NEJMoa2114228 DOI: https://doi.org/10.1056/NEJMoa2114228
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384: 1412-1423.
https://doi.org/10.1056/NEJMoa2101765 DOI: https://doi.org/10.1056/NEJMoa2101765
Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021; 384: 1970. DOI: https://doi.org/10.1056/NEJMc2104281
https://doi.org/10.1056/NEJMoa2110475 DOI: https://doi.org/10.1056/NEJMoa2110475
Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Clin Exp Vaccine Res 2021; 10: 198.
https://doi.org/10.7774/cevr.2021.10.2.198 DOI: https://doi.org/10.7774/cevr.2021.10.2.198
Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol 2021; 93: 5231-5232.
https://doi.org/10.1002/jmv.27036 DOI: https://doi.org/10.1002/jmv.27036
McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.
https://doi.org/10.1016/j.jaad.2021.03.092 DOI: https://doi.org/10.1016/j.jaad.2021.03.092
Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults. J Eur Acad Dermatol Venereol 2021; 35: e846-e847.
https://doi.org/10.1111/jdv.17577 DOI: https://doi.org/10.1111/jdv.17577
Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel) 2021; 9: 572.
https://doi.org/10.3390/vaccines9060572 DOI: https://doi.org/10.3390/vaccines9060572
Tessas I, Kluger N. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol 2021; 35: e620-e622.
https://doi.org/10.1111/jdv.17422 DOI: https://doi.org/10.1111/jdv.17422
Rodríguez-Jiménez P, Chicharro P, Cabrera L-M, Seguí M, Morales-Caballero Á, Llamas-Velasco M, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep 2021; 12: 58-59.
https://doi.org/10.1016/j.jdcr.2021.04.014 DOI: https://doi.org/10.1016/j.jdcr.2021.04.014
Brosh-Nissimov T, Sorek N, Yeshayahu M, Zherebovich I, Elmaliach M, Cahan A, et al. Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19. Vaccine 2021; 39: 5729-5731.
https://doi.org/10.1016/j.vaccine.2021.08.088 DOI: https://doi.org/10.1016/j.vaccine.2021.08.088
Shasha D, Bareket R, Sikron FH, Gertel O, Tsamir J, Dvir D, et al. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. Clin Microbiol Infect 2022; 28: 130-134.
https://doi.org/10.1016/j.cmi.2021.09.018 DOI: https://doi.org/10.1016/j.cmi.2021.09.018
Chen I-L, Chiu H-Y. Association of herpes zoster with COVID-19 vaccination: a systematic review and meta-analysis. J Am Acad Dermatol 2023; 89: 370-371.
https://doi.org/10.1016/j.jaad.2023.03.031 DOI: https://doi.org/10.1016/j.jaad.2023.03.031
Jeffery MM, D'onofrio G, Paek H, Platts-Mills TF, Soares WE, Hoppe JA, et al. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 pandemic in the US. JAMA Intern Med 2020; 180: 1328-1333.
https://doi.org/10.1001/jamainternmed.2020.3288 DOI: https://doi.org/10.1001/jamainternmed.2020.3288
Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ 2012: 344: d7762.
https://doi.org/10.1136/bmj.d7762 DOI: https://doi.org/10.1136/bmj.d7762
Wan EYF, Chui CSL, Wang Y, Ng VWS, Yan VKC, Lai FTT, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. The Lancet Regional Health-Western Pacific 2022; 21: 100393.
https://doi.org/10.1016/j.lanwpc.2022.100393 DOI: https://doi.org/10.1016/j.lanwpc.2022.100393
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021; 595: 572-577.
https://doi.org/10.1038/s41586-021-03653-6 DOI: https://doi.org/10.1038/s41586-021-03653-6
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Shir Azrielant, Yair Levin, Alon Peled, Liat Samuelov, Eli Sprecher, Mor Pavlovsky
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
